IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9708614 B1

PDFFull Text
Date of Patent:
Jul. 18, 2017

Filed:

Aug. 15, 2016

Antisense design

Applicant:

Roche Innovation Center Copenhagen A/s, Basel, CH;

Inventors:

Signe M. Christensen, Kobenhavn, DK;

Nikolaj Dam Mikkelsen, Bronshoj, DK;

Miriam Frieden, Kobenhavn, DK;

Henrik Frydenlund Hansen, Ringsted, DK;

Troels Koch, Copenhagen S, DK;

Daniel Sejer Pedersen, Valby, DK;

Christoph Rosenbohm, Birkerod, DK;

Charlotte Albaek Thrue, Hampshire, GB;

Majken Westergaard, Birkerod, DK;

Assignee:

Roche Innovation Center Copenhagen A/S, Hoersholm, DK;

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Tracy Vivlemore

Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7088 (2006.01); C07H 21/00 (2006.01); C07H 21/04 (2006.01); C07H 21/02 (2006.01); C12N 15/11 (2006.01); C07H 19/04 (2006.01); C07H 19/06 (2006.01); C07H 19/16 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7088 (2013.01); C07H 19/04 (2013.01); C07H 19/06 (2013.01); C07H 19/16 (2013.01); C07H 21/00 (2013.01); C07H 21/02 (2013.01); C07H 21/04 (2013.01); C12N 15/111 (2013.01); C12N 15/1137 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/344 (2013.01); C12N 2320/30 (2013.01); C12N 2320/51 (2013.01);
Abstract

A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Find Patent Forward Citations

Loading…